Skip to navigation Skip to content

High-risk neuroblastoma (NBL) Program in Pharmaceutical Benefits Scheme (PBS) 012-25070740

Expand/Collapse all sectionsExpand all


High-risk NBL restriction and item codes

Do not share this attachment externally. See Freedom of Information – Information Publication Scheme.

\\INTERNAL.DEPT.LOCAL\Shared\NAT\SERDELEXCEL\WORKPRODIMP\Operation Blueprint Migration\RDT Release Icons\32w\icon-hidden-attachment.pngPBS NBL restriction and item codes

High-risk NBL dosage chart

Table 1

Body Surface Area (BSA)

Quantity (units)

Repeats

0.25 to <0.5 m2

100

1

0.5 to <0.75 m2

200

1

0.75 to 1.5 m2

200

2

>1.5 m2

300

2

Contact details

PBS Complex Drugs Programs

Form

High-risk neuroblastoma - eflornithine - initial authority application form (PB384)

Services Australia website

High-risk-neuroblastoma

External website

PBS schedule for High-risk-neuroblastoma

FAQs from Service Officers

Table 1: see Table 2 in Processing Complex Authority Required Listings for FAQs about Complex programs.

Item

Description

1

Is there an age restriction for patients applying for PBS-subsidised treatment of NBL?

No. There is no age limitation.

2

Are questions and answers (Q&A) attached to relevant restrictions of NBL available in the National Drug Reference Database (NDRD)?

No. NBL authority applications are assessed by Dynamic Q&A in the Online PBS Authorities (OPA) system.

For troubleshooting see Resources > Dynamic Question and Answers (DQA) resources in Dosage calculators and charts for Pharmaceutical Benefits Scheme (PBS).

3

Is the quantity and repeats approved based on patient size?

Yes. The prescriber should request an appropriate quantity and number of repeats based on the patient’s Body Surface Area (BSA) according to the TGA approved PI (dosage chart above).